Skip to content

Study · Randomized controlled trial · n = 87 · 2023

6 results

Intranasal Oxytocin as Add-On Treatment for Inpatients with Severe Mental Illness: A Randomized Clinical Trial.

Grossman-Giron A, Maoz H, Nitzan U, Kivity Y, Zilcha-Mano S, Bloch Y, Mendlovic S, Tzur Bitan D

Neuropsychobiology5 Jan 2023Cited by 11 (Europe PMC)

PMID36603563 (opens in a new tab)DOI10.1159/000528314 (opens in a new tab)PepBankPUB-36603563
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In psychiatric inpatients with severe mental illness, add-on intranasal oxytocin gave significantly larger symptomatic improvements than placebo.

    In plain wordsIn psychiatric inpatients, oxytocin nasal spray added to usual care gave larger symptom improvements than placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseWeekly symptomatic improvement
    Study

    n = 87

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · intranasal · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    Patients receiving OT demonstrated significantly larger symptomatic improvements (B = -0.01, t [437] = -2.36, p = 0.01).
    1 context sentence
    Summary · context
    Patients (N = 87, 71.3% female participants) were administered intranasal oxytocin/placebo twice daily for 4 weeks, as add-on to usual care.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In psychiatric inpatients, depression gains were larger in the oxytocin group than in the placebo group.

    In plain wordsIn psychiatric inpatients, depression improved more with oxytocin nasal spray than with placebo, although it also improved with placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseDepression
    Study

    n = 87

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · intranasal · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    Larger gains were also observed for depression (B = -0.14, p < 0.001 in the OT group, B = -0.06, p = 0.02 in the placebo group)
    1 context sentence
    Summary · context
    Patients (N = 87, 71.3% female participants) were administered intranasal oxytocin/placebo twice daily for 4 weeks, as add-on to usual care.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In psychiatric inpatients, gains in general distress were larger in the oxytocin group than in the placebo group.

    In plain wordsIn psychiatric inpatients, general distress improved more with oxytocin nasal spray than with placebo, although it also improved with placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseGeneral distress
    Study

    n = 87

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · intranasal · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    general distress (B = -0.57, p < 0.001 in the OT group, B = -0.29, p = 0.02 in the placebo group).
    1 context sentence
    Summary · context
    Patients (N = 87, 71.3% female participants) were administered intranasal oxytocin/placebo twice daily for 4 weeks, as add-on to usual care.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In psychiatric inpatients, intranasal oxytocin had no significant effect on anxiety.

    In plain wordsIn psychiatric inpatients, oxytocin nasal spray did not significantly change anxiety.

    Peptide
    Oxytocin
    Outcome
    No significant changeAnxiety
    Study

    n = 87

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · intranasal · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    No significant effect was observed for anxiety, the working alliance, or attachment.
    1 context sentence
    Summary · context
    Patients (N = 87, 71.3% female participants) were administered intranasal oxytocin/placebo twice daily for 4 weeks, as add-on to usual care.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In psychiatric inpatients, intranasal oxytocin had no significant effect on the working alliance.

    In plain wordsIn psychiatric inpatients, oxytocin nasal spray did not significantly change the bond with the therapist.

    Peptide
    Oxytocin
    Outcome
    No significant changeWorking alliance with the therapist
    Study

    n = 87

    Comparator
    Placebo
    Outcome group
    Social behavior and cognition · Mental health and mood
    Studied dose
    Dose not stated · intranasal · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    No significant effect was observed for anxiety, the working alliance, or attachment.
    1 context sentence
    Summary · context
    Patients (N = 87, 71.3% female participants) were administered intranasal oxytocin/placebo twice daily for 4 weeks, as add-on to usual care.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In psychiatric inpatients, intranasal oxytocin had no significant effect on attachment.

    In plain wordsIn psychiatric inpatients, oxytocin nasal spray did not significantly change attachment.

    Peptide
    Oxytocin
    Outcome
    No significant changeAttachment
    Study

    n = 87

    Comparator
    Placebo
    Outcome group
    Social behavior and cognition · Mental health and mood
    Studied dose
    Dose not stated · intranasal · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    No significant effect was observed for anxiety, the working alliance, or attachment.
    1 context sentence
    Summary · context
    Patients (N = 87, 71.3% female participants) were administered intranasal oxytocin/placebo twice daily for 4 weeks, as add-on to usual care.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.